This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.

Lexon former director Sonpal disqualified by UK CMA over anticompetitive drug practices

( January 11, 2022, 10:24 GMT | Official Statement) -- MLex Summary: The UK's Competition and Markets Authority has said it has secured the disqualification of former Lexon director Pritesh Sonpal for his role in anticompetitive practices. In March 2020, the CMA found that Lexon, King Pharmaceuticals and Alissa Healthcare covertly shared sensitive data to skew the UK drugs market and maintain high prices of nortriptyline, an antidepressant. Last year, Lexon lost its appeal against the CMA's decision to fine the company....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections